|Year : 2018 | Volume
| Issue : 2 | Page : 170-176
A review of clinical experience with progesterone-only injectable contraceptives at OAUTHC, Ile-Ife
Adebimpe O Ijarotimi1, Boluwatife S Idowu2, Oluwaseun O Sowemimo1, Adebanjo B Adeyemi1, Ernest O Orji1
1 Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo University/Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria
2 Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo University/Teaching Hospitals Complex, Ile-Ife, Osun State; Nigeria Airforce, Mother and Child Hospital, Badagry, Lagos, Nigeria
|Date of Web Publication||17-Aug-2018|
Dr. Adebimpe O Ijarotimi
Department of Obstetrics, Gynaecology and Perinatology, College of Health Sciences, Obafemi Awolowo University/Teaching Hospitals Complex, Ile-Ife, Osun- State
Source of Support: None, Conflict of Interest: None
Background: Progestogen-only injectable contraceptives (POICs) remain the most popular contraceptive method in Nigeria. Considering how widely used POICs are worldwide, there is little published evidence of their safety and effectiveness. There is also a paucity of research to determine associations between the influence of age and parity and the preferred choice of POICs in women.
Aim: This study was to determine the use prevalence and the influence of age and parity on the preferred choice of POIC, and also the reasons for discontinuation among users of POICs at the family planning clinics of OAUTHC, Ile-Ife.
Materials and Methods: A retrospective record of 324 women who chose POICs out of a total of 1,029 clients seen at the family planning units of the hospital was collected for the period between January and December 2015. Information relevant to this study objectives was extracted using a purpose-designed proforma. Data were analyzed with SPSS version 16, and results were presented as frequencies and percentages. Pearson Chi-square test was used as test of significance where applicable and a P value < 0.05 was considered statistically significant.
Results: The prevalence of POIC during the study period was 31.49%. Depo-Provera (depot medroxyprogesterone acetate [DMPA]) was the most popular injectable preferred by the women. Age and parity had significant effects on the preferred injectable contraception with P values of 0.032 (CI 0.088-0.099) and 0.002 (CI 0.009-0.013), respectively, as younger clients with lower parity preferred Noristerat while preference for DMPA increased with age and parity. Majority (67%) did not experience any side effect; secondary amenorrhea was the most common side effect experienced by 27% of the clients. Only 34% continued with the method for the duration of study while 66% discontinued for different reasons.
Conclusion: POICs are very effective and safe long-acting reversible method of contraception. While DMPA may be the more popular overall choice, norethisterone enanthate (NET-EN) is preferable in younger women of low parity.
Keywords: Depoprovera; Ile-Ife; Noristerat.
|How to cite this article:|
Ijarotimi AO, Idowu BS, Sowemimo OO, Adeyemi AB, Orji EO. A review of clinical experience with progesterone-only injectable contraceptives at OAUTHC, Ile-Ife. Trop J Obstet Gynaecol 2018;35:170-6
|How to cite this URL:|
Ijarotimi AO, Idowu BS, Sowemimo OO, Adeyemi AB, Orji EO. A review of clinical experience with progesterone-only injectable contraceptives at OAUTHC, Ile-Ife. Trop J Obstet Gynaecol [serial online] 2018 [cited 2022 Jan 27];35:170-6. Available from: https://www.tjogonline.com/text.asp?2018/35/2/170/239159
| Introduction|| |
Decision making concerning fertility control is, for many people, a deeply personal and sensitive issue, often involving religious or philosophical convictions. Family planning refers to a conscious effort by a couple to limit or space the number of children they want to have through the use of contraceptive methods. Nigeria constitutes 2% of the world population but accounts for 10% of global maternal deaths, about 60,000 maternal deaths occur annually in Nigeria. Knowledge of contraception is widespread in Nigeria; 85% of women and 95% of men report knowing about a contraceptive method, but the contraceptive prevalence rate is low. Fifteen percent of currently married women use a contraceptive method, an increase of only 2 percentage points from the 2003 Nigeria Demographic and Health Survey (NDHS). Ten percent of currently married women report using a modern method. Injectables remain the most popular contraceptive method among them.
The high level of awareness about contraception but very low level of use has been established in studies in Nigeria.,,, The 2013 NDHS results indicate that the total fertility rate (TFR) is 5.5 births per woman. Overall, Nigerian women have about one child more than the number they want. This high fertility rate accounts for Nigeria's high maternal, infant, and neonatal mortalities.
Steroid sex hormones may be injected intramuscularly to provide a depot, which, depending on the drug, dosage, and formulation, may provide contraception for 1 month, 6 months, or even 1 year. A pure progestin may be used, or the injection may consist of a combination of a progestin with an estrogen. Most of these regimens prevent ovulation by suppression of anterior pituitary function. There are two commonly used injectable progestogen-only contraceptives that have been available in many countries in the world since 1983. These are depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN).
The pharmacological composition of DMPA is medroxyprogesterone acetate, a semi-synthetic derivative of progesterone that features the same pharmacological profile but is remarkably more potent. DMPA inhibits gonadotropin-releasing hormone pulsatility and gonadotropin secretion, and the luteinizing hormone (LH) is much more suppressed than the follicle-stimulating hormone (FSH), thereby effectively preventing ovulation. This results in the estradiol levels being low in long-term users. NET-EN is administered at the dose of 200 mg every 60 days, and inhibits fertility through a mixed, two-phase mechanism: during the first portion of the drug's half-life span, the contraceptive effect is exerted at the hypothalamic level, whereas later on when ovulation is restored, the action is likely to be peripheral on the cervical mucus and/or the endometrium.,
Ideally, both progestogen-only injectable contraceptives (POICs) should be started within 5 days of the menstrual cycle, to rule out pregnancy. Injection in the first 7 days of menses results in immediate ovulation suppression. However, POICs can be commenced at any stage of the menstrual cycle, providing that the woman is not pregnant. The quick start method means that she does not have to wait for her next menses to begin. The 14-day rule should be observed, which means that she must abstain from, or have protected sexual intercourse, for 14 days after the administration of the injection if started in mid-cycle.
Progestogen-only injectables are very effective methods of fertility control with published failure rates of 0.3% in the first year of use. After the injections are discontinued, there may be considerable delay in reestablishment of regular ovulation and corresponding true menstrual bleeding. However, fertility rates are essentially normal at about 18 months after discontinuation.
An advantage of the drug is that its use is independent of coitus or a daily activity such as pill taken. Therefore being discreet, it enables the women to maintain secrecy about their use of contraception, especially in some African settings where the use of contraception is discouraged due to cultural or religious reasons. POICs also offer the advantage of not requiring special storage (making them suitable for use in tropical countries like Nigeria). Lactating mothers can successfully breast feed their babies as the POICs do not adversely affect milk composition, quality, or quantity. Reported noncontraceptive benefits of POICs include reduction in frequency of sickle cell crises, reduction of menstrual cycle disorders, less dysmenorrhoea, less symptoms of premenstrual tension, and reduction in seizure frequency in women with epilepsy.
Bone mineral density may be reduced among those who receive injections of medroxyprogesterone. Changes in bone density appear similar to those seen during lactation. Subgroups of long-term users of Depo-Provera may experience a decrease in spinal bone density that appears to be reversible following discontinuation. Changes in the menstrual cycle are inevitable with injectable contraceptives, and are commonly referred to as “menstrual chaos.” Changes in menstrual patterns may result in amenorrhea and breakthrough bleeding.
Withdrawal bleeding may be heavy, irregular, or absent, and there may be spotting. Amenorrhea is a predictable side effect of DMPA and NET-EN owing to the inhibition of both ovulation and follicular development. Amenorrhea may be generally more acceptable to women than prolonged or frequent bleeding. Side effects other than irregular bleeding that may be encountered include a delay in ovulation when discontinued; thus when a delay in return to fertility, mildly androgenic effects may increase existing depression, acne, and hair loss. Others are weight gain, headache, nervousness, abdominal discomfort, dizziness, and fatigue.
Nigeria has one of the highest maternal mortality ratios in sub-Saharan Africa, and ranks as the country with the second highest number of maternal deaths in the world. Use of long-acting reversible methods is proposed as a strategy to reverse undesirable maternal health consequences in developing countries.,
Considering how widely used DMPA is worldwide, there is little published evidence of its safety and effectiveness. There is also paucity of research to determine associations between the influence of age and parity and the preferred choice of POICs in women.
This study aims to determine the use prevalence, the influence of age and parity on the preferred choice of POIC, side effects, and discontinuation rate as well as the reasons for discontinuation among users of POICs at the family planning clinics of our hospitals.
| Materials and Methods|| |
This study reviewed the clinical experience with POICs chosen by women accessing family planning services in a Nigerian teaching hospital family planning unit. The health facility consists of two hospitals and two primary health care centers. These hospital units serve not only the health administrative zone in which they are located but also receive clients from other parts of Osun State and some parts of Oyo, Ondo, and Ekiti States which are neighboring states.
A descriptive study.
Data collection method
A retrospective record of 324 women who chose POICs at the family planning units of the hospital out of a total of 1,029 clients seen was collected for the period between January and December 2015. After due counseling by family planning nurses and physicians, a full medical history was taken and clinical examination as well as pregnancy test were performed to exclude known contraindications to POIC and pregnancy.
DMPA marketed as Depo-Provera® and NET-EN marketed as Noristerat® are the two POICs available in Nigeria. A dose of 200 mg NET-EN or 150 mg DMPA was injected into the gluteal/deltoid muscle within the first 7 days of a normal menstrual period where menstrual dates were known. It was also given after abortion and 6 weeks after delivery in breastfeeding mothers who were yet to resume menstruation. Repeat injections and observations were done after every 60 days for those receiving NET-EN and every 90 days for clients on DMPA. At each visit, all the complaints volunteered by the patient were documented. The weight, blood pressure, and result of urinalysis were recorded. A patient was considered lost to follow up if she defaulted more than twice from scheduled injections.
A total of 324 clients had POICs within the period under study out of which 18 had incomplete records and were therefore excluded from the study leaving a total of 306 files which were complete. Information about age, marital status, highest level of education, parity, previously used contraceptive methods, preferred injectable contraception, side effects experienced by the POIC acceptors, discontinuation, and reasons for discontinuation were extracted from the hospital records using a purpose-designed proforma.
Analysis was done with respect to use prevalence, profile of the acceptors, and discontinuation rate over the period of study. The influence of age and parity was considered on the choice of preferred injectable contraceptive. Data were cleaned and analyzed with Statistic Package for Social Sciences version 16; results were presented as frequencies and percentages. Pearson Chi-square test was used as test of significance where applicable and a P value < 0.05 was considered statistically significant.
Limitations of the study
The retrospective nature of this study prevented direct access to the clients and thereby increased the incidence of incomplete records. Also being a hospital-based study, it cannot give a true picture of the use prevalence of POICs for this environment because of other sources of obtaining the injectable contraceptive such as primary health care centers and patent medicine vendors. This review, however, was able to address the study objectives and provided information that can be used for further studies, training of contraceptive providers, program planning, and policy formulation.
| Results|| |
A total of 1,029 clients were seen at the two family planning units of the hospital between January to December 2015; 324 of these clients accepted POICs after due counseling. The use prevalence of POICs during the study period was 31.49%. Eighteen of the clients had incomplete records and were therefore excluded from the study leaving a total of 306 files which are complete. The POICs acceptors were between the ages of 20 and 45 years with mean ± standard deviation (SD) of 32.68 ± 4.76 years as shown in [Figure 1].
[Table 1] revealed that majority (60%) of the acceptors were educated up to secondary school level. Parity of the acceptors in [Table 2] ranged from 1 to 7 with a mean ± SD of 3.37 ± 1.34. [Table 3] showed that fresh acceptors accounted for 35% of the POICs clients, about 25% of the acceptors migrated from natural family planning to modern contraception, while the remaining 40% switched from other modern methods. Depo-Provera (DMPA) was the most popular injectable preferred by 63% of the women while 37% opted for Noristerat (NET-EN) as depicted in [Figure 2].
Age and parity had significant effects on the preferred injectable contraception with P values of 0.032 (CI 0.088-0.099) and 0.002 (CI 0.009-0.013), respectively, as younger clients with lower parity preferred Noristerat (NET-EN) while preference for Depo-Provera (DMPA) increased with age and parity as shown in [Table 4] and [Table 5]. [Table 6] revealed that majority (67%) did not experience any side effect; 27% experienced secondary amenorrhea which was the commonest side effect. The discontinuation rate in [Figure 3] revealed that only 34% continued with the method for the duration of study while 66% discontinued for different reasons. [Table 7] showed that the reasons given for discontinuation were mainly menstrual abnormalities in 49% of the women and inability to keep up with the appointments in 43%. There was no accidental pregnancy recorded during the study period.
| Discussion|| |
The use prevalence of POICs during the study period was 31.49%. This is higher than the incidence of 12.6%, 22.1%, and 23.3% obtained from earlier studies at Ile-Ife, Oshogbo, and Calabar  in Southwest and South South Nigeria, respectively. This rise may be attributable to the slight increase in the national contraceptive prevalence rate from 13% to 15% and increasing acceptability of injectable contraceptives having become the most popular contraceptive method. Religious and sociocultural influences on the choice of contraception can explain the higher values of 64.6% and 50.7% obtained from Kano  and Zaria  both in Northwest Nigeria.
The POI injectable acceptors were between the ages of 20 and 45 years with mean ± SD of 32.68 ± 4.76 years. This is comparable with the age profile in similar studies by Adeyemi et al. and Njoku et al. About 63% of them were in the age group of 20 to 34 years; clients older than 35 years accounted for less than 37% of the study population. This was not unexpected because ages 20 to 35 years represent the peak reproductive period with high fecundability, then declining fertility in later years.
Contraceptive use is positively associated with women's level of education and contraceptive use increases with educational attainment. Majority (60%) of the acceptors in this study were educated up to secondary school level while less than 4% had no education at all. This is in keeping with findings from the national surveys that 37% of women who have more than a secondary education use a contraceptive method, as compared with only 3% of women with no education.
Parity of the acceptors in this study ranged from 1 to 7 with more than half (52%) between Para 1 and 3 while parity greater than 6 constituted only 4%. This may be due to the fact that clients with higher number of children were likely to be older and likely to have completed their family size, and may find longer acting contraceptives like Intrauterine Contraceptive Device (IUCD) and implants more suitable than injectables.
Fresh acceptors constituted 35% of the POI clients in this study while 43% switched from other modern methods such as condoms, pills, IUCD, emergency contraception, and implants to POI method. These values were slightly lower than 41.3% and 58.7% obtained for fresh acceptors and previous use of modern contraceptives obtained from a similar study. The difference may be due to variations in contraceptive counseling skills and individual client's perception of the different contraceptive methods.
The finding that 25% of the acceptors migrated from natural family planning methods like withdrawal and periodic abstinence to an effective modern method of contraception like POI is not surprising considering the high failure rates associated with such natural methods of family planning. In this study, the popularity of Depo-Provera (DMPA) which was preferred by 63% of the women versus 37% for Noristerat (NET-EN) is in keeping with findings from several studies on POI.,, This popularity may be due to the reduced frequency of clinical visits associated with DMPA compared with NET-EN.
The influence of age and parity on the preferred choice of POI is a unique aspect of this study which was not considered in previous studies on POI that were reviewed. Age and parity had significant effects on the preferred injectable contraception as younger clients with lower parity preferred Noristerat (NET-EN) while preference for Depo-Provera (DMPA) increased with age and parity. This perhaps may be due to the fact that Noristerat (NET-EN) is suited to women who prefer the reduced likelihood of amenorrhea and require a shorter return time to fertility. This reflects the needs of younger women with lower parity.
The finding that majority (67%) of the clients in this study did not experience any side effect is a welcome development which will encourage such users. Secondary amenorrhea is the most common side effect experienced by 27% of the acceptors which is consistent with findings from several similar studies.,,,,, The discontinuation rate from this study was 66%. Only 34% continued with the method for the duration of study while 66% discontinued for different reasons which is unacceptably high. Although this discontinuation rate is slightly lower than the finding from a similar study in Port-Harcourt which reported a 77% cumulative discontinuation rate, it is, however, much higher than 19% and 22% reported in studies from Calabar and Osogbo, respectively., Four noncomparative studies from the United States demonstrated discontinuation rates among DMPA users ranging from 41% to 77% at 1 year. Another study also showed cumulative discontinuation rates up to 79% among DMPA users at 5 years.,,,
Reasons given for discontinuation were mainly menstrual abnormalities in 49% of the women and inability to keep up with the appointments in 43%. Regular menstruation is perceived as a sign of healthy reproductive function and general well-being. There are myths about the absence of menstruation leading to a buildup of bad blood in the body and making the woman ill. Also breakthrough/unpredictable bleeding can be inconvenient as well as a source of embarrassment. Therefore, irregular menses is a major cause of apprehension and anxiety in these women with little tolerance for the cause. These factors may be responsible for the high discontinuation rate which is in keeping with the reasons cited from several studies.,,,
Appropriate counseling to disabuse the myths, repeated reassurance, and short-term use of combined oral pills to correct the abnormal bleeding patterns may help to reduce the rate of discontinuation in those experiencing these side effects. There was no accidental pregnancy recorded in the clients during the study period which confirmed the effectiveness of POI as evidenced by other similar studies.,
| Conclusions and Recommendations|| |
POICs are very effective and safe long-acting reversible contraceptives. While DMPA may be the more popular overall choice, NET-EN is preferable in younger women of lower parity. Majority of the women studied tolerated POICs well but the rate of discontinuation was rather high. Adequate counseling and information to prepare the minds of the clients about the menstrual disruption, constant reassurance, support, and measures to correct abnormal bleeding can help to reduce the discontinuation rate.
Information technology also has a role to play in the form of programmed short message service (sms) reminders that can be sent to the clients around the due date of their injections. This will help to reduce the incidence of clients failing to turn up for their appointments and enhance continuation.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Grewal M, Burkman RT. Contraception and Family Planning. In: Decheney AH, editor. Current Diagnosis and Treatment in Obstetrics and Gynaecology, Lange Medical Book. 9th
ed. New York: McGraw-Hill Companies; c2003. pp 631-50.
National Population Commission (NPC) [Nigeria] and ICF International. 2014. Nigeria Demographic and Health Survey; 2013. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF International.
Nigerian National Reproductive Health Strategic Framework and Plan 2002-2006. Federal Ministry of Health, Abuja; 2002. pp 4-6.
Abiodun OM, Balogun OR. Sexual activity and contraceptive use among young female students of tertiary educational institution in Ilorin, Nigeria. Contraception 2009;79:146-9.
Oye-Adeniran BA, Adewole IF, Odeyemi KA, Ekanem EE, Umoh AV. Contraceptive prevalence among young women in Nigeria. J Obstet Gynaecol 2005;25:182-5.
Amazigo U, Silva N, Kaufman J, Obikeze DS. Sexual activity and contraceptive knowledge and use among in-school adolescents in Nigeria. Int Fam Plan Perspect 1997;23:28-33.
Okpani AOU, Okpani JU. Sexual activity and contraceptive use among female adolescents: A report from Port Harcourt. Afr J Reprod Health 2000;4:40-7.
Monjok E, Smesny A, Ekabua JE, Essien EJ. Contraceptive practices in Nigeria: Literature review and recommendation for future policy decisions. Open Access J Contraception 2010;1:9-22.
Benagiano G, Primiero FM. Long-acting contraceptive, present status. Drugs 1983;25:570-609.
Adams BDP. A comparison of progestogen only injectable contraceptives. Prof Nurs Today 2015;19:22-7.
Fotherby K, Saxena BN, Shrimanker K, Hingorani V, Takker D, Diczfalusy E, et al
. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate. Fertil Steril 1980;34:131-9.
Nelson AL. DMPA: Battered and bruised but still needed and used in the USA. Expert Rev Obstet Gynecol 2010;5:673-86.
Sekadde-Kigondu C, Mwathe EG, Ruminjo JK, Nichols D, Katz K, Jessencky K, et al
. Acceptability and discontinuation of Depo-Provera, IUCD and combined pill in Kenya. East Afr Med J 1996;73:786-94.
The ESHRE Workshop Group. Hum Reprod Update 2003;9:373-86.
Njoku CO, Emechebe CI, Iklaki CU, Njoku AN, Ukaga JT. Progestogen-Only Injectable Contraceptives: The Profile of the Acceptors, Side Effects and Discontinuation in a Low Resource Setting, Nigeria. Open J Obstet Gynecol 2016;6:189-95.
Burkman R, Amnon B. Contraception and Family Planning. In: Decheney, AH, editor. Current Diagnosis and Treatment Obstetrics and Gynaecology, Lange Medical Book. New York: McGraw-Hill Companies; c2013. pp 928-47.
UN: Contraceptive Commodities for Women's Health, in Key Data and Findings. New York: United Nations Commission on Life-Saving Commodities for Women and Children 2012:1-29.
UNFPA: United Nations High Level Meeting on Reproductive Health Commodity Security. New York: United Nations; 2011. pp 1-40.
Ijarotimi AO, Bakare B, Badejoko OO, Fehintola AO, Loto OM, Orji EO, et al
. Contraceptive uptake among women attending family planning clinic in a Nigerian tertiary health facility: A 6 year review. Int J Reprod Contraceptive Obstet Gynecol 2015;4:721-4.
Adeyemi AS, Adekanle DA. Progestogen-Only Injectable Contraception: Experience of Women in Osogbo, Southwestern Nigeria. Ann Afr Med 2012;11:27-31.
] [Full text]
Muhammad Z, Maimuna DG. Contraceptive trend in a tertiary facility in North Western Nigeria: A 10-year review. Niger J Basic Clin Sci 2014;11:99-103. [Full text]
Ameh N, Sule ST. Contraceptive Choices among Women in Zaria, Nigeria. Niger J Clin Pract 2007;10:205-7.
] [Full text]
Ojule JD, Oriji VK, Okongwu C. A Five-Year Review of the Complications of Progestogen only Injectable Contraceptive at the University of Port-Harcourt Teaching Hospital. Niger J Med 2010;19:87-95.
Igwegbe AO, Ugboaja JO. Clinical Experience with Injectable Progestogen-Only Contraceptives at Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. J Med Med Sci 2010;1:345-9.
Potter LS, Dalberth BT, Canamar R, Betz M. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department. Contraception 1997;56:305-12.
Polaneczky M, Guarnaccia M, Alon J, Wiley J. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Fam Plan Perspect 1996;28:174-8.
Westfall JM, Main DS, Barnard L. Continuation rates among injectable contraceptive users. Fam Plan Perspect 1996;28:275-7.
Schwallie PC, Assenzo JR. Contraceptive use–efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973;24:331-9.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7]